

NEXERA

TGF β R2 \times PD-1: Exploring New Possibilities
with Cancer Immunotherapy

A Randomized, Double-Blind Study of FOLFOX + Bevacizumab With or Without INCA33890 (TGF β R2 \times PD-1 Bispecific Antibody)

1L MSS CRC | Phase 3 | INCA033890-303 (NCT07284849)




The efficacy and safety of the investigational compounds discussed have not been established.
There is no guarantee that these compounds will become commercially available for the use(s) under investigation.

The information on this card is current as of May 8, 2026.

Incyte.com
© 2026, Incyte.
MSL-PD-TGFB-US-0003 05/26
Incyte and the Incyte logo are
registered trademarks of Incyte.

1L MSS CRC | PHASE 3 | INCA033890-303

A Randomized, Double-Blind Study of FOLFOX + Bevacizumab With or Without INCA33890 (TGF β R2 \times PD-1 Bispecific Antibody)^{1,2}



Select Inclusion Criteria

- Stage IV colorectal adenocarcinoma not amenable to curative resection
- No prior systemic treatment for unresectable or metastatic disease
 - Patients who received adjuvant and/or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment
- Measurable disease per RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1

Select Exclusion Criteria

- MSI-H/dMMR
- Untreated and/or progressing CNS metastases
- History of other malignancy within 2 years
- Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years

For more information, please visit:



<https://clinicaltrials.gov/study/NCT07284849>

For more information, visit [IncyteClinicalTrials.com](https://clinicaltrials.com) or contact us at clintrials@incyte.com

1L, first line; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CNS, central nervous system; CRC, colorectal cancer; dMMR, mismatch repair deficient; FOLFOX, leucovorin calcium, fluorouracil, and oxaliplatin; iv, intravenous; MSI-H, microsatellite instability-high; MSS, microsatellite stable; PD-(L)1, programmed cell death protein (ligand) 1; pMMR, mismatch repair proficient; PS, performance status; Q2W, every 2 weeks; R, randomized; RECIST, Response Evaluation Criteria in Solid Tumors; TGF β R2, transforming growth factor β receptor 2.
1. ClinicalTrials.gov. Accessed Feb 2026. <https://clinicaltrials.gov/study/NCT07284849> 2. Data on file. Incyte Corporation.